Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Non Operating Income (2016 - 2025)

Avalo Therapeutics' Non Operating Income history spans 12 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 81.64% year-over-year to $6.2 million; the TTM value through Dec 2025 reached -$3.7 million, down 105.39%, while the annual FY2025 figure was -$5.2 million, 115.43% down from the prior year.
  • Non Operating Income reached $6.2 million in Q4 2025 per AVTX's latest filing, up from -$11.4 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $88.5 million in Q2 2024 to a low of -$88.5 million in Q1 2024.
  • Average Non Operating Income over 5 years is $3.0 million, with a median of -$1.0 million recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 10863.64% in 2021, then soared 2541.09% in 2024.
  • A 5-year view of Non Operating Income shows it stood at -$1.2 million in 2021, then plummeted by 252.2% to -$4.2 million in 2022, then increased by 0.79% to -$4.1 million in 2023, then surged by 909.81% to $33.5 million in 2024, then plummeted by 81.64% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Non Operating Income are $6.2 million (Q4 2025), -$11.4 million (Q3 2025), and -$5000.0 (Q2 2025).